These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19751880)

  • 1. Sebaceous lesions and their associated syndromes: part II.
    Eisen DB; Michael DJ
    J Am Acad Dermatol; 2009 Oct; 61(4):563-78; quiz 579-80. PubMed ID: 19751880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sebaceous lesions and their associated syndromes: part I.
    Eisen DB; Michael DJ
    J Am Acad Dermatol; 2009 Oct; 61(4):549-60; quiz 561-2. PubMed ID: 19751879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
    Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
    Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muir-Torre syndrome.
    Cohen PR; Kohn SR; Davis DA; Kurzrock R
    Dermatol Clin; 1995 Jan; 13(1):79-89. PubMed ID: 7712655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
    Abbas O; Mahalingam M
    J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muir-Torre syndrome: a case report and review of the literature.
    Pettey AA; Walsh JS
    Cutis; 2005 Mar; 75(3):149-55. PubMed ID: 15839358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muir-Torre syndrome.
    Ponti G; Ponz de Leon M
    Lancet Oncol; 2005 Dec; 6(12):980-7. PubMed ID: 16321766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muir-Torre syndrome: Diagnostic and screening guidelines.
    Jones B; Oh C; Mangold E; Egan CA
    Australas J Dermatol; 2006 Nov; 47(4):266-9. PubMed ID: 17034469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical follow-up and presence of visceral tumors in 12 patients with sebaceous gland tumors].
    Mercader P; García-Melgares ML; Roche E; Sánchez-Carazo JL; Alegre-de Miquel V
    Actas Dermosifiliogr; 2008 Sep; 99(7):532-9. PubMed ID: 18682166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sebaceous gland adenoma of the tarsal conjunctiva in a patient with Muir-Torre syndrome.
    Font RL; Rishi K
    Ophthalmology; 2003 Sep; 110(9):1833-6. PubMed ID: 13129885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Torre-Muir syndrome. Sebaceous gland neoplasms, keratoacanthomas, multiple internal cancers and heredity].
    Worret WI; Burgdorf WH; Fahmy A; Pitha J
    Hautarzt; 1981 Oct; 32(10):519-24. PubMed ID: 7298331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Muir-Torre syndrome: a 25-year retrospect.
    Schwartz RA; Torre DP
    J Am Acad Dermatol; 1995 Jul; 33(1):90-104. PubMed ID: 7601953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muir-Torre syndrome: clinical features and molecular genetic analysis.
    Esche C; Kruse R; Lamberti C; Friedl W; Propping P; Lehmann P; Ruzicka T
    Br J Dermatol; 1997 Jun; 136(6):913-7. PubMed ID: 9217825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal immunohistochemical screening of sebaceous neoplasms for Muir-Torre syndrome: Putting the cart before the horse?
    Kim RH; Nagler AR; Meehan SA
    J Am Acad Dermatol; 2016 Nov; 75(5):1078-1079. PubMed ID: 27745640
    [No Abstract]   [Full Text] [Related]  

  • 15. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families.
    Ponti G; Ponz de Leon M; Losi L; Di Gregorio C; Benatti P; Pedroni M; Scarselli A; Riegler G; Lembo L; Pellacani G; Seidenari S; Rossi G; Roncucci L
    Br J Dermatol; 2005 Jun; 152(6):1335-8. PubMed ID: 15949004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions.
    Marazza G; Masouyé I; Taylor S; Prins C; Gaudin T; Saurat JH; French LE
    Arch Dermatol; 2006 Aug; 142(8):1039-42. PubMed ID: 16924054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations on the performance of immunohistochemistry for mismatch repair gene proteins in cases of sebaceous neoplasms and keratoacanthomas with reference to Muir-Torre syndrome.
    Fernandez-Flores A
    Am J Dermatopathol; 2012 Jun; 34(4):416-22. PubMed ID: 22123265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sebaceous neoplasms with mismatch repair protein expressions and the frequency of co-existing visceral tumors.
    Lee BA; Yu L; Ma L; Lind AC; Lu D
    J Am Acad Dermatol; 2012 Dec; 67(6):1228-34. PubMed ID: 22552002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An association between sebaceous carcinoma and microsatellite instability in immunosuppressed organ transplant recipients.
    Harwood CA; Swale VJ; Bataille VA; Quinn AG; Ghali L; Patel SV; Dove-Edwin I; Cerio R; McGregor JM
    J Invest Dermatol; 2001 Feb; 116(2):246-53. PubMed ID: 11180000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.
    Roberts ME; Riegert-Johnson DL; Thomas BC; Rumilla KM; Thomas CS; Heckman MG; Purcell JU; Hanson NB; Leppig KA; Lim J; Cappel MA
    Genet Med; 2014 Sep; 16(9):711-6. PubMed ID: 24603434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.